222987-62-4

Usage

Uses

Used in Pharmaceutical Industry:
1(2H)-Pyridinecarboxylic acid, 4-(4-carboxyphenyl)-3,6-dihydro-, 1-(1,1-dimethylethyl) ester, or telmisartan, is used as an antihypertensive agent for the treatment of high blood pressure. It functions by blocking the action of angiotensin II, leading to the relaxation and widening of blood vessels, which in turn facilitates easier blood flow and lowers blood pressure. This application is particularly beneficial in managing and reducing the risk of stroke, heart attack, and death in patients with high blood pressure.
Used in Combination Therapy:
Telmisartan is also used in combination with other medications to enhance the overall effectiveness of high blood pressure treatment. The combination therapy approach allows for a more comprehensive management of the condition, potentially leading to better patient outcomes and a reduced risk of associated complications.
Used in Cardiovascular Health:
Due to its ability to lower blood pressure and reduce the risk of stroke, heart attack, and death, telmisartan plays a significant role in maintaining cardiovascular health. It is particularly useful for patients with a history of hypertension or those at risk of developing cardiovascular diseases.
Used in Research and Development:
In addition to its clinical applications, telmisartan is also utilized in research and development for the study of angiotensin II receptor antagonists and their potential applications in various medical conditions. This includes the investigation of their effects on blood pressure regulation, cardiovascular health, and the development of new therapeutic strategies for hypertension and related conditions.

Upstream product

• 14047-29-1 4-carboxyphenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 106-37-6 1.4-dibromobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 163209-96-9 tert-butyl 4-(4-bromophenyl)-4-hydroxypiperidine-1-carboxylate 

Downstream Products

• 149353-75-3 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)benzoic acid 

Relevant academic research and scientific papers

Preparation method for synthesizing 1-tert-butyloxycarbonyl -4-(4- carboxyphenyl) piperidine (by machine translation)

The preparation method 1 - of synthesizing)-tert-butyloxycarbonyl - 4 4 4 4 4-carboxyphenyl, piperidine comprises the following steps: reacting dibromobenzene or iodobromide as raw material, with N - Boc - 4 - piperidone to obtain the target product 2, with intermediate 3, and preparing intermediate 3 by hydrogenation or hydrogenation to obtain the target product through intermediate 4, preparation intermediate 3 and carrying out hydrogenation reaction with the carbon dioxide to obtain the target product, which is, suitable for industrial production 4, in large, scale 5. by using common reagent, raw material cost, and the reaction is carried out with carbon dioxide. (by machine translation)

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Sulfonyl derivatives

Sulfonyl derivatives represented by general formula (I), salts of the same, and solvates of both: and application of them as drugs: [wherein R1is hydrogen, hydroxyl, nitro or the like; R2and R3are each independently hydrogen, halogeno or the like; R4and R5are each dependently hydrogen, halogeno or the like; Q1is an optionally substituted saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group or the like; Q2is a single bond, oxygen or the like; Q3is, e.g., a group represented by formula (a): T1is carbonyl or the like; and X1and X2are each independently methylidyne or nitrogen]. These compounds exhibit potent Fxa inhibiting activities and serve as excellent anticoagulants which speedily exert satisfactory and persistent anti-thrombotic effects through oral administration and little cause adverse effects.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.